Oncologists Favor CAR T-Cell Therapy for Early Relapsed Myeloma
Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.
Related Articles
Acknowledging the Importance of Clinical Judgment in Breast Cancer
Fengting Yan, MD, PhD, discusses the challenge of balancing clinical judgment with genomic test results in breast cancer.
Evaluating Role of Loncastuximab in Third-Line DLBCL After CAR T
During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of using loncastuximab in a patient with relapsed…
Clinical Decision-Making With PERSIST-2: Optimizing Therapy for Anemic Myelofibrosis Patients With Splenomegaly
Panelists discuss how Janus kinase (JAK) inhibitors like pacritinib offer crucial treatment options for myelofibrosis patients with severe thrombocytopenia (platelet counts <50,000 ), highlighting its…
Avutometinib Plus Defactinib Gains FDA Approval in KRAS+ Ovarian Cancer
Avutometinib given with defactinib is now approved for the treatment of adult patients with recurrent low-grade serous, KRAS-positive ovarian cancer.
The Multidisciplinary Approach to cGVHD Diagnosis
Panelists discuss how clinicians typically diagnose chronic graft-vs-host disease (cGVHD) based on clinical features rather than biopsies, except in atypical or uncertain cases.
IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma
Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.
Shorter CAR T Monitoring Safe After Early CRS/NE Resolution
Olalekan O Oluwole, MD, MBBS, discusses a study investigating shorter monitoring times post CAR T therapy.
Optimizing Myelofibrosis Therapy: A Comprehensive Comparison of JAK Inhibitor Clinical Trials From Design to Outcomes
Panelists discuss how Janus kinase (JAK) inhibitor dosing strategies must be carefully tailored for anemic myelofibrosis patients, with clinical experience suggesting starting at lower doses…
FDA Lifts Clinical Hold on Tab-Cel Application in EBV+ PTLD
With the clinical hold on the tab-cel application lifted, phase 2 and 3 trials of the T-cell immunotherapy in patients with PTLD may resume.
FDA Accepts Narsoplimab BLA Resubmission for Transplant-Associated TMA
The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been accepted by the FDA.